|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1992-2-12
|
|
pubmed:abstractText |
In 7 patients 10 cycles (5 to 21 days, dosage: 30 to 430 mg, median 138 mg) of OKT3 therapy were performed after liver transplantation. In all patients reactivation of an EBV-infection with hepatitis was observed. Two patients treated with high dosages (430 mg respectively 195 mg) developed lymphoproliferative lesions. In one patient with persistent EBV-infection (dosage: 360 mg) a B-cell-lymphoma was diagnosed. This patient died 26 months after transplantation.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0044-2771
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
422-5
|
|
pubmed:dateRevised |
2009-11-11
|
|
pubmed:meshHeading |
pubmed-meshheading:1662431-Female,
pubmed-meshheading:1662431-Graft Rejection,
pubmed-meshheading:1662431-Hepatitis, Viral, Human,
pubmed-meshheading:1662431-Herpesvirus 4, Human,
pubmed-meshheading:1662431-Humans,
pubmed-meshheading:1662431-Liver Transplantation,
pubmed-meshheading:1662431-Lymphoma, B-Cell,
pubmed-meshheading:1662431-Lymphoproliferative Disorders,
pubmed-meshheading:1662431-Male,
pubmed-meshheading:1662431-Muromonab-CD3,
pubmed-meshheading:1662431-Postoperative Complications,
pubmed-meshheading:1662431-Recurrence
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
[Experiences with monoclonal antibody orthoclone OKT3 following liver transplantation].
|
|
pubmed:affiliation |
Chirurgische Universitätsklinik, Universität Hamburg.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
